Andarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Usage

1. Establish your baseline before starting: note any pre-existing visual sensitivities or low-light adaptation issues, as S-4 will temporarily affect rod photoreceptor function and you need a clear reference point.
2. Start with one 10 mg tablet in the morning on Day 1 and assess your response for the first 48 hours before increasing — even if your target dose is higher.
3. Once your introductory phase is complete, divide your total daily dose into a morning tablet and an early-afternoon tablet; avoid late-evening dosing as this is when low-light vision impairment is most noticeable and most disruptive.
4. Take each tablet with a small meal or snack — S-4 is lipophilic and absorption consistency improves when administered with dietary fat.
5. Monitor vision quality actively throughout your cycle: a mild yellow-green tint or slower dark-adaptation is expected at therapeutic doses; if the tint is severe or vision is compromised in normal lighting, reduce dose by 10 mg immediately.
6. Plan your cycle length to a maximum of 8 weeks followed by a minimum 4-week off period and appropriate PCT; S-4 suppresses endogenous testosterone production and post-cycle hormonal recovery must be supported pharmacologically.

Warnings

Frequently asked questions

What is Andarine (S-4) most commonly used for during a cutting phase?

Andarine is primarily used during a cut to preserve lean muscle mass while body fat decreases, producing a harder, more vascular appearance. Its partial agonist activity at androgen receptors in skeletal muscle prevents the catabolism that typically accompanies a caloric deficit, allowing users to maintain — and in some cases improve — muscle fullness and visible vascularity without retaining subcutaneous water.

Why does Andarine S-4 cause yellow or tinted vision, and is it permanent?

The visual side effect occurs because S-4's metabolite M1 binds androgen receptors in the retinal rod photoreceptors, impairing low-light and colour adaptation. This is a dose-dependent and fully reversible effect — the yellow-green tint and difficulty adjusting to dim conditions resolve within days to a few weeks after dose reduction or cessation. It is not a sign of permanent retinal damage.

How do you minimise the vision side effects of Andarine while still getting results?

Splitting the total daily dose into two smaller administrations — typically morning and early afternoon — lowers peak plasma concentration and reduces maximum retinal AR occupancy at any single time point. Most users who stay within 25–50 mg/day and divide doses this way report manageable or negligible visual disturbance. Doses above 50 mg/day significantly increase the likelihood and severity of visual symptoms.

How do the 10 mg tablets from Elbrus Pharmaceuticals make dosing Andarine more practical?

A 10 mg tablet format allows users to dial in their exact daily intake with one-tablet precision — 25 mg, 37.5 mg, or 50 mg per day can be approximated cleanly across split doses. This level of control is harder to achieve with liquid S-4 preparations, where volumetric measurement error is common. Each tablet's declared potency is backed by batch-level HPLC verification, so the dose on the label is the dose in the tablet.

Are Elbrus Pharmaceuticals Andarine tablets supplied in blister packs, and does that affect shelf stability?

Yes, the 60-tablet supply is presented in blister strip packaging, which provides individual compartment isolation from moisture and light — two primary factors that degrade SARM potency over time. Blister packs also make it straightforward to track daily consumption and maintain a consistent dosing schedule, which is particularly important for a compound like S-4 where consistent dosing intervals help manage peak plasma levels and minimise vision-related side effects. (2) angle_used

Manufacturer

The quality commitment behind Elbrus Pharmaceuticals' S-4 tablet line is best understood not as a set of procedures, but as a response to a specific failure mode the brand's founders observed in the research-compound market: the systematic disconnection between raw-material certificates and finished-tablet reality. A supplier's certificate of analysis confirms what was in a drum of API — it says nothing about what survived granulation, compression, and blending to reach the individual tablet a user swallows. Elbrus treats this gap as the central quality problem to solve, not an administrative formality to paper over. For the Andarine 10mg tablet specifically, the solution is a two-checkpoint release architecture: incoming API is assessed for identity and purity before it enters the manufacturing process, and the finished compressed tablet — the actual product, not the bulk powder — is re-analysed by HPLC for confirmed potency and by LAL assay for endotoxin content before a lot number is assigned for distribution. Both results are retained as lot-referenced records. This structure means that when a user reads "10 mg Andarine S-4" on the label, the number corresponds to a documented analytical finding from the finished tablet matrix — not an extrapolation from upstream paperwork.